A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Treatment options for patients with recurrent brain metastases are extremely limited. This study was designed to determine the safety and efficacy of temozolomide in the treatment of recurrent or progressive brain metastases.
Patients and methods: Forty-one patients (11 men, 30 women) with a median KPS of 80 were treated with temozolomide 150 mg/m2/day (200 mg/m2/day if no prior chemotherapy) for 5 days; treatment cycles were repeated every 28 days. Primary tumor types included 22 non-small cell lung, 10 breast, three melanoma, two small cell lung, two rectal, one ovarian and one endometrial cancer.
Results: There were five episodes of grade 3 thrombocytopenia and one grade 4 leukopenia. Significant non-hematologic toxicity possibly related to temozolomide included pneumonitis , constipation , and elevated liver enzymes . Thirty-four patients were assessed for radiographic response; two had a partial response, 15 stable disease and 17 progressed. Both objective responses were seen in patients with non-small cell lung cancer. Overall median survival was 6.6 months.
Conclusions: Single agent temozolomide achieved disease control (PR or SD) in 41% of patients with recurrent brain metastases from a variety of primary malignancies with minimal toxicity. Therefore, temozolomide may be a reasonable treatment option for some patients with recurrent brain metastases.
- Raymond, E, Izbicka, E, Soda, H, Gerson, SL, Dugan, M, VonHoff, DD (1997) Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 3: pp. 1769-1774
- Stupp, R, Ostermann, S, Leyvraz, S, Csaijka, C, Buclin, T, Decosterd, LA (2001) Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Amer Soc Clin Oncol 20: pp. 59a
- Fleming, TR (1982) One sample multiple testing procedure for phase II clinical trials. Biometrics 38: pp. 143-151
- Kaplan, EL, Meier, P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: pp. 457-481
- Christodoulou, C, Bafaloukos, D, Kosmidis, P, Papakostas, P, Skarlos, DV (2001) Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: pp. 249-254
- Bindal, RK, Sawaya, R, Leavens, ME, Hess, KR, Taylor, SH (1995) Reoperation for recurrent metastatic brain tumors. J Neurosurg 83: pp. 600-604
- Arbit, E, Wronski, M, Burt, M, Galicich, JH (1995) The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer 76: pp. 765-773
- Davey, P, O'Brien, PF, Schwartz, ML, Cooper, PW (1994) A phase I/II study of salvage radiosurgery in the treatment of recurrent brain metastases. Br J Neurosurg 8: pp. 717-723
- Alexander, E, Moriarty, TM, Davis, RB, Wen, PY, Fine, HA, Black, PM, Kooy, HM, Loeffler, JS (1995) Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87: pp. 34-40
- Coia, LR (1992) The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 23: pp. 222-238
- Abdel-Wahab, MM, Wolfson, AH, Raub, W, Landy, H, Feun, L, Sridhar, K, Brandon, AH, Mahmood, S, Markoe, AM (1997) The role of hyperfractionated re-irradiation in metastatic brain disease: a single institutional trial. Am J Clin Oncol 20: pp. 158-160
- Lesser, GJ (1996) Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin N Am 7: pp. 527-535
- Kaba, SE, Kyritsis, AP, Hess, K, Yung, WKA, Mercier, R, Dakhil, S, Jaeckle, KA, Levin, VA (1997) TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15: pp. 1063-1070
- Alexander, EI, Loeffler, JS (1996) Recurrent brain metastases. Neurosurg Clin N Am 7: pp. 517-526
- Franciosi, V, Cocconi, G, Michiara, M, Di Costanzo, F, Fosser, V, Tonato, M, Carlini, P, Boni, C, Di Sarra, S (1999) Front-line chemotherapy with Cisplatin and Etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma. Cancer 85: pp. 1599-1605
- A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases
Journal of Neuro-Oncology
Volume 53, Issue 3 , pp 259-265
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- brain metastases
- lung cancer
- Industry Sectors